Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial

Masafumi Ikeda,Masatoshi Kudo,Hiroshi Aikata,Hiroaki Nagamatsu,Hiroshi Ishii,Osamu Yokosuka,Takuji Torimura,Manabu Morimoto,Kenji Ikeda,Hiromitsu Kumada,Tosiya Sato,Ikuko Kawai,Toru Yamashita,Hiroshi Horio,Takuji Okusaka

Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial

2018

Masafumi Ikeda
Masatoshi Kudo
Hiroshi Aikata
Hiroaki Nagamatsu
Hiroshi Ishii
Osamu Yokosuka
Takuji Torimura
Manabu Morimoto
Kenji Ikeda
Hiromitsu Kumada
Tosiya Sato
Ikuko Kawai
Toru Yamashita
Hiroshi Horio
Takuji Okusaka

Background This prospective study investigated the superiority of transarterial chemoembolization (TACE) with miriplatin over TACE with epirubicin regarding overall survival (OS) in patients with unresectable hepatocellular carcinoma (HCC).

Keywords:

Carcinoma
Randomized controlled trial
Prospective cohort study
Miriplatin
Organoplatinum Compounds
Hepatocellular carcinoma
Epirubicin
Oncology
Survival analysis
Medicine
Internal medicine
Colorectal surgery
General surgery
in patient
Gastroenterology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations